Global eye care leader Alcon has announced that its Clareon Monofocal intraocular lens (IOL) has achieved EU MDR compliance certification via TÜV SÜD, reinforcing its status as a premier choice for predictable surgical outcomes.
- Alcon's Clareon Monofocal IOL is now EU MDR certified by TÜV SÜD.
- The lens provides sharp distance vision and functional intermediate visual acuity.
- Over 150 million Clareon IOLs have been implanted globally since 2018.
- Meets ESCRS criteria for the 'enhanced monofocal' category.
Alcon, a global powerhouse in ophthalmology, has officially announced that the Clareon® Monofocal intraocular lens (IOL) has received certification for Medical Device Regulation (MDR) compliance from TÜV SÜD. This certification is backed by a robust body of clinical evidence, including more than 30 peer-reviewed publications that validate the lens's ability to deliver superior optical performance.
According to Amar Vyas, Country Head India at Alcon, the choice of an IOL must align with a patient's specific lifestyle and the surgeon's objectives. The Clareon Monofocal is designed to offer exceptional optical clarity, allowing surgeons to achieve reliable distance vision while enhancing intermediate visual outcomes, which is critical for modern daily activities.
Why This Matters
BozokMedia analysis shows that the shift toward 'enhanced monofocals' represents a critical evolution in cataract surgery. Patients are no longer satisfied with a single point of focus; they require functional vision for intermediate tasks (like using a tablet or seeing a car dashboard) without the visual disturbances often associated with multifocal lenses. By securing EU MDR certification, Alcon solidifies its competitive edge in the stringent European and global markets.
"The integration of glistening-free BioMaterial with STABLEFORCE® haptics marks a paradigm shift in ensuring long-term stability and visual purity for cataract patients."
From a technical standpoint, the Clareon lens is crafted from a pristine hydrophobic acrylic BioMaterial. This material is specifically engineered to minimize haze and glistenings—common issues in older IOL generations. Clinical data confirms that Clareon IOLs remain glistening-free for up to nine years, providing long-term peace of mind for both the surgeon and the patient.
Furthermore, the lens features a proprietary edge designed to reduce glare and prevent posterior capsular opacification (PCO). The inclusion of STABLEFORCE® Haptics ensures that the lens maintains exceptional axial and rotational stability, which is paramount for the predictability of the refractive outcome.
The Clareon family is extensive, including the PanOptix Trifocal and Vivity Extended Vision lenses. While the Monofocal focuses on distance and intermediate range, the PanOptix version aims for complete spectacle independence for a full range of vision, with 91.6% of patients achieving this goal.
| Feature | Clareon Monofocal | Standard Monofocal |
|---|---|---|
| Visual Range | Distance + Intermediate | Primarily Distance |
| BioMaterial | Glistening-free Acrylic | Standard Acrylic |
| Certification | EU MDR & ESCRS | Standard Regulatory |
Frequently Asked Questions
Q1: What does EU MDR certification mean for the end-user?
It ensures that the medical device meets the highest current European safety and performance standards, reducing the likelihood of post-operative complications.
Q2: Is the Clareon Monofocal suitable for patients with astigmatism?
Yes, Alcon offers a Toric version of the Clareon Monofocal specifically designed to correct corneal astigmatism during cataract surgery.
